Sunflower Pharmaceutical Group Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Public

  • Employees
  • 5,025

Employees

  • Stock Symbol
  • 002737

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.75
  • (As of Thursday Closing)

Sunflower Pharmaceutical Group General Information

Description

Sunflower Pharmaceutical Group Co Ltd is engaged in Research, development, production and sales of various traditional Chinese medicines and chemical drugs (including biopharmaceuticals).

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Number 18, Donghu Road, Yingbin Road Central District
  • Daoli District
  • Harbin, Heilongjiang 150078
  • China
+86 0451
Primary Industry
Pharmaceuticals
Stock Exchange
SHE
Vertical(s)
Corporate Office
  • Number 18, Donghu Road, Yingbin Road Central District
  • Daoli District
  • Harbin, Heilongjiang 150078
  • China
+86 0451

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sunflower Pharmaceutical Group Stock Performance

As of 19-Nov-2026, Sunflower Pharmaceutical Group’s stock price is $1.75. Its current market cap is $1.02B with 584M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.75 $1.80 $1.62 - $2.18 $1.02B 584M 5.1M -$0.03

Sunflower Pharmaceutical Group Financials Summary

As of 30-Sep-2026, Sunflower Pharmaceutical Group has a trailing 12-month revenue of $399M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 646,072 949,190 1,369,559 1,730,806
Revenue 399,348 322,327 470,638 805,708
EBITDA (21,726) (14,290) 110,350 212,519
Net Income (20,421) (35,853) 68,573 158,185
Total Assets 801,667 761,547 798,054 970,842
Total Debt 31,923 16,569 1,232 3,741
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sunflower Pharmaceutical Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sunflower Pharmaceutical Group‘s full profile, request access.

Request a free trial

Sunflower Pharmaceutical Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sunflower Pharmaceutical Group Investments & Acquisitions (4)

Sunflower Pharmaceutical Group’s most recent deal was a Merger/Acquisition with Dongxu Pharmaceutical for . The deal was made on 22-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dongxu Pharmaceutical 22-Sep-2026 Merger/Acquisition Distributors (Healthcare)
Hainan Huihai 27-Sep-2023 Merger/Acquisition Distributors (Healthcare)
Glory (China) 13-Apr-2022 Corporate Food Products
PMSTAR 09-Nov-2021 Corporate Pharmaceuticals
To view Sunflower Pharmaceutical Group’s complete investments and acquisitions history, request access »

Sunflower Pharmaceutical Group ESG

Risk Overview

Risk Rating

Updated September, 30, 2023

34.15 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 435

Rank

Percentile

To view Sunflower Pharmaceutical Group’s complete esg history, request access »

Sunflower Pharmaceutical Group Exits (1)

Sunflower Pharmaceutical Group’s most recent exit was on 27-Sep-2023 from Hainan Huihai. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Hainan Huihai 27-Sep-2023 Completed
To view Sunflower Pharmaceutical Group’s complete exits history, request access »

Sunflower Pharmaceutical Group FAQs

  • When was Sunflower Pharmaceutical Group founded?

    Sunflower Pharmaceutical Group was founded in 2005.

  • Where is Sunflower Pharmaceutical Group headquartered?

    Sunflower Pharmaceutical Group is headquartered in Harbin, China.

  • What is the size of Sunflower Pharmaceutical Group?

    Sunflower Pharmaceutical Group has 5,025 total employees.

  • What industry is Sunflower Pharmaceutical Group in?

    Sunflower Pharmaceutical Group’s primary industry is Pharmaceuticals.

  • Is Sunflower Pharmaceutical Group a private or public company?

    Sunflower Pharmaceutical Group is a Public company.

  • What is Sunflower Pharmaceutical Group’s stock symbol?

    The ticker symbol for Sunflower Pharmaceutical Group is 002737.

  • What is the current stock price of Sunflower Pharmaceutical Group?

    As of 19-Nov-2026 the stock price of Sunflower Pharmaceutical Group is $1.75.

  • What is the current market cap of Sunflower Pharmaceutical Group?

    The current market capitalization of Sunflower Pharmaceutical Group is $1.02B.

  • What is Sunflower Pharmaceutical Group’s current revenue?

    The trailing twelve month revenue for Sunflower Pharmaceutical Group is $399M.

  • What is Sunflower Pharmaceutical Group’s annual earnings per share (EPS)?

    Sunflower Pharmaceutical Group’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process